RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has received notice of Intent to Grant a patent from the European Patent Office for the treatment of patients with MS. The patent covers use of the Company’s proprietary molecule Thymosin beta 4 (Tβ4) in a composition for treating or reducing deterioration of, injury or damage to tissue due to MS. The patent expiry is January 13, 2026.
{iframe}http://www.regenerx.com/2016-08-29-RegeneRx-Receives-Notice-of-Intent-to-Grant-Patent-for-the-Treatment-of-Patients-with-Multiple-Sclerosis-in-EU{/iframe}